Severe gonadotoxic insult manifests early in young girls treated for Ewing sarcoma. Mörse, H., Elfving, M., Turkiewicz, A., Andersen, C. Y., & Øra, I. Medicine, 95(33):e4512, August, 2016.
doi  abstract   bibtex   
We prospectively investigated anti-Müllerian hormone (AMH) as a measure of ovarian insult in young females during and after treatment for Wilms tumor (WT), osteosarcoma (OS), and Ewing sarcoma (ES).Twenty-one female childhood cancer patients, with a mean age of 7.9 years (range 0.6-17), entered the study. Levels of AMH, follicle-stimulating hormone (FSH), and luteinizing hormone were monitored at diagnosis and every 3 to 4 months during, and regularly for a mean of 2.6 years after treatment.A profound decline in AMH was seen in the majority of the 21 study patients 3 to 4 months after the beginning of treatment, the exception being patients with WT, of whom 60% showed no such decline. During the remaining treatment, all patients except those with WT not treated with whole abdominal radiotherapy or stem cell transplantation (SCT) had AMH below detection limit.After completion of treatment, patients with OS and WT (without whole abdominal radiotherapy and SCT) recovered in AMH and had FSH in the normal range. In contrast, ES patients showed no AMH recovery and highly fluctuating FSH in the first years of follow-up, except for the 2 youngest patients, who had a late, slow AMH recovery.In conclusion, young female ES patients already showed signs of severe ovarian dysfunction during the first years after cancer treatment similar to patients treated with SCT and abdominal radiotherapy, in contrast to females with WT and OS. Fertility counseling and information concerning fertility preservation procedures should be considered before starting to treat young females with ES.
@article{morse_severe_2016,
	title = {Severe gonadotoxic insult manifests early in young girls treated for {Ewing} sarcoma},
	volume = {95},
	issn = {1536-5964},
	doi = {10.1097/MD.0000000000004512},
	abstract = {We prospectively investigated anti-Müllerian hormone (AMH) as a measure of ovarian insult in young females during and after treatment for Wilms tumor (WT), osteosarcoma (OS), and Ewing sarcoma (ES).Twenty-one female childhood cancer patients, with a mean age of 7.9 years (range 0.6-17), entered the study. Levels of AMH, follicle-stimulating hormone (FSH), and luteinizing hormone were monitored at diagnosis and every 3 to 4 months during, and regularly for a mean of 2.6 years after treatment.A profound decline in AMH was seen in the majority of the 21 study patients 3 to 4 months after the beginning of treatment, the exception being patients with WT, of whom 60\% showed no such decline. During the remaining treatment, all patients except those with WT not treated with whole abdominal radiotherapy or stem cell transplantation (SCT) had AMH below detection limit.After completion of treatment, patients with OS and WT (without whole abdominal radiotherapy and SCT) recovered in AMH and had FSH in the normal range. In contrast, ES patients showed no AMH recovery and highly fluctuating FSH in the first years of follow-up, except for the 2 youngest patients, who had a late, slow AMH recovery.In conclusion, young female ES patients already showed signs of severe ovarian dysfunction during the first years after cancer treatment similar to patients treated with SCT and abdominal radiotherapy, in contrast to females with WT and OS. Fertility counseling and information concerning fertility preservation procedures should be considered before starting to treat young females with ES.},
	language = {eng},
	number = {33},
	journal = {Medicine},
	author = {Mörse, Helena and Elfving, Maria and Turkiewicz, Aleksandra and Andersen, Claus Yding and Øra, Ingrid},
	month = aug,
	year = {2016},
	pmid = {27537574},
	pmcid = {PMC5370800},
	keywords = {Adolescent, Anti-Mullerian Hormone, Bone Neoplasms, Child, Child, Preschool, Combined Modality Therapy, Female, Follicle Stimulating Hormone, Humans, Infant, Kidney Neoplasms, Luteinizing Hormone, Osteosarcoma, Primary Ovarian Insufficiency, Sarcoma, Ewing, Wilms Tumor},
	pages = {e4512}
}
Downloads: 0